Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant

Abstract EN

Background.

Posttransplant lymphoproliferative disorders (PTLDs) occur after solid organ transplantation.

Treatment guidelines include reduction in immunosuppression (RIS), radiation, rituximab, chemotherapy, and immunological agents.

We present a rare case of recurrent diffuse large B-cell lymphoma presenting as a PTLD in a heart transplant patient treated with autologous blood stem cell transplant (ASCT) after failure of conventional therapy.

Case Presentation.

A 66-year-old male presented with a neck mass.

He has a history of Hodgkin’s disease status after staging laparotomy with splenectomy and heart transplantation due to dilated nonischemic cardiomyopathy 8 years prior to the development of PTLD.

His examination was remarkable for right submandibular swelling.

An excisional biopsy confirmed the diagnosis of diffuse large B-cell NHL.

Patient received RIS, rituximab, chemotherapy, and radiation therapy with a complete remission.

His lymphoma relapsed and he subsequently was treated with RICE salvage chemotherapy and consolidative high-dose chemotherapy with BEAC regimen followed by ASCT resulting in a complete remission.

Conclusion.

Patients with PTLD present a difficult therapeutic challenge.

In this case, the patient’s prior history of Hodgkin’s disease, splenectomy, and a heart transplant appear to be unique features, the significance of which is unclear.

ASCT might be a promising therapy for patients with relapsed or refractory PTLD.